Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy GRAYBUG VISION stock | 15.9

Own GRAYBUG VISION stock in just a few minutes.

Updated . What changed?

Fact checked

GRAYBUG VISION, INC. is a biotechnology business based in the US. GRAYBUG VISION shares (GRAY) are listed on the NASDAQ and all prices are listed in US Dollars. GRAYBUG VISION employs 24 staff and has a market cap (total outstanding shares value) of USD$310.4 million.

How to buy shares in GRAYBUG VISION

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for GRAYBUG VISION. Find the stock by name or ticker symbol: GRAY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GRAYBUG VISION reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$15.9, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of GRAYBUG VISION, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of GRAYBUG VISION. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

GRAYBUG VISION share price

Use our graph to track the performance of GRAY stocks over time.

GRAYBUG VISION shares at a glance

Information last updated 2020-10-19.
Latest market closeUSD$15.9
52-week rangeUSD$12.5 - USD$20.74
50-day moving average USD$14.575
200-day moving average USD$14.575
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy GRAYBUG VISION stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GRAYBUG VISION price performance over time

Historical closes compared with the close of $15.9 from 2020-10-19

1 week (2020-10-14) -1.67%
1 month (2020-09-18) N/A
3 months (2020-07-18) N/A
6 months (2020-04-18) N/A
1 year (2019-10-18) N/A
2 years (2018-10-18) N/A
3 years (2017-10-18) N/A
5 years (2015-10-18) N/A


Gross profit TTM USD$0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation USD$310.4 million

TTM: trailing 12 months

Shorting GRAYBUG VISION shares

There are currently 174,598 GRAYBUG VISION shares held short by investors – that's known as GRAYBUG VISION's "short interest". This figure is up from 0 last month.

There are a few different ways that this level of interest in shorting GRAYBUG VISION shares can be evaluated.

GRAYBUG VISION's "short interest ratio" (SIR)

GRAYBUG VISION's "short interest ratio" (SIR) is the quantity of GRAYBUG VISION shares currently shorted divided by the average quantity of GRAYBUG VISION shares traded daily (recently around 646659.25925926). GRAYBUG VISION's SIR currently stands at 0.27. In other words for every 100,000 GRAYBUG VISION shares traded daily on the market, roughly 270 shares are currently held short.

To gain some more context, you can compare GRAYBUG VISION's short interest ratio against those of similar companies.

  • Kodiak Sciences (KOD.US): 12.34
  • REGENXBIO (RGNX.US): 10.89
  • Kala Pharmaceuticals (KALA.US): 5.43

However GRAYBUG VISION's short interest can also be evaluated against the total number of GRAYBUG VISION shares, or, against the total number of tradable GRAYBUG VISION shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GRAYBUG VISION's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 GRAYBUG VISION shares in existence, roughly 10 shares are currently held short) or 0.0174% of the tradable shares (for every 100,000 tradable GRAYBUG VISION shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GRAYBUG VISION.

Find out more about how you can short GRAYBUG VISION stock.

GRAYBUG VISION share dividends

We're not expecting GRAYBUG VISION to pay a dividend over the next 12 months.


Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.

Frequently asked questions

More guides on finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site